Literature DB >> 21692989

Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.

Alessia Usardi1, Amy M Pooler, Anjan Seereeram, C Hugh Reynolds, Pascal Derkinderen, Brian Anderton, Diane P Hanger, Wendy Noble, Ritchie Williamson.   

Abstract

Recent reports have demonstrated that interactions between the microtubule-associated protein tau and the nonreceptor tyrosine kinase Fyn play a critical role in mediating synaptic toxicity and neuronal loss in response to β-amyloid (Aβ) in models of Alzheimer's disease. Disruption of interactions between Fyn and tau may thus have the potential to protect neurons from Aβ-induced neurotoxicity. Here, we investigated tau and Fyn interactions and the potential implications for positioning of these proteins in membrane microdomains. Tau is known to bind to Fyn via its Src-homology (SH)3 domain, an association regulated by phosphorylation of PXXP motifs in tau. Here, we show that Pro216 within the PXXP(213-216) motif in tau plays an important role in mediating the interaction of tau with Fyn-SH3. We also show that tau interacts with the SH2 domain of Fyn, and that this association, unlike that of Fyn-SH3, is influenced by Fyn-mediated tyrosine phosphorylation of tau. In particular, phosphorylation of tau at Tyr18, a reported target of Fyn, is important for mediating Fyn-SH2-tau interactions. Finally, we show that tyrosine phosphorylation influences the localization of tau to detergent-resistant membrane microdomains in primary cortical neurons, and that this trafficking is Fyn-dependent. These findings may have implications for the development of novel therapeutic strategies aimed at disrupting the tau/Fyn-mediated synaptic dysfunction that occurs in response to elevated Aβ levels in neurodegenerative disease.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692989     DOI: 10.1111/j.1742-4658.2011.08218.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  34 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

Review 2.  Fyn in Neurodevelopment and Ischemic Brain Injury.

Authors:  Renatta Knox; Xiangning Jiang
Journal:  Dev Neurosci       Date:  2015-02-17       Impact factor: 2.984

3.  Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-β Oligomer-Triggered Synapse Loss.

Authors:  Suho Lee; Santiago V Salazar; Timothy O Cox; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

4.  AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.

Authors:  J Nicholas Cochran; Pauleatha V Diggs; N Miranda Nebane; Lynn Rasmussen; E Lucile White; Robert Bostwick; Joseph A Maddry; Mark J Suto; Erik D Roberson
Journal:  J Biomol Screen       Date:  2014-08-25

5.  The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

Review 6.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

7.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  EMBO J       Date:  2017-09-01       Impact factor: 11.598

8.  Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease.

Authors:  Lynn M Bekris; Steve Millard; Franziska Lutz; Gail Li; Doug R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby W Tsuang; Chang-En Yu; Elaine R Peskind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-08-27       Impact factor: 3.568

Review 9.  Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.

Authors:  Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz
Journal:  Nat Rev Neurol       Date:  2017-12-15       Impact factor: 42.937

10.  Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.

Authors:  Nadia Mazzaro; Erica Barini; Maria Grazia Spillantini; Michel Goedert; Paolo Medini; Laura Gasparini
Journal:  J Neurosci       Date:  2016-02-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.